We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
COVID-19 Vaccine Development: GeoVax and Sino Biological Establish Exclusive Bioreagent Supply Agreement
Product News

COVID-19 Vaccine Development: GeoVax and Sino Biological Establish Exclusive Bioreagent Supply Agreement

COVID-19 Vaccine Development: GeoVax and Sino Biological Establish Exclusive Bioreagent Supply Agreement
Product News

COVID-19 Vaccine Development: GeoVax and Sino Biological Establish Exclusive Bioreagent Supply Agreement

Credit: rawpixel

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "COVID-19 Vaccine Development: GeoVax and Sino Biological Establish Exclusive Bioreagent Supply Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, has announced that Sino Biological, Inc. will be its exclusive supplier of SARS-CoV-2 (COVID-19) bioreagent research products.

Under the terms of the agreement, Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in COVID-19 vaccine development underway at GeoVax. Sino Biological will also obtain exclusive rights to research-use-only (RUO) reagents developed jointly by the companies.  Financial terms were not disclosed. Sino Biological was the first to market with mammalian cell-made COVID-19 viral recombinant proteins and offers a full range of these and other bioreagents to complement and aid in COVID-19 vaccine development and has a large selection of coronavirus research-grade products. GeoVax’s use of recombinant viruses to generate virus-like particles (VLPs) in vivo has demonstrated considerable immune response for other viruses in a number of human clinical trials.

Advertisement